Intelligent Bio 2026 Q1 Earnings Revenue Surges 27.5% Despite 50% Narrowed Loss Per Share

Intelligent Bio (INBS), ranked by market capitalization, reported its fiscal 2026 Q1 earnings on Nov 12, 2025. The company delivered a 27.5% revenue increase to $1.11 million, surpassing expectations. However, the net loss widened to $2.99 million, reflecting ongoing financial challenges. The company provided no specific financial guidance, focusing instead on regulatory advancements and international expansion.

Revenue

The revenue growth was driven by cartridge sales, which accounted for 57.6% of total revenue, alongside the addition of 33 new customer accounts, expanding the customer base to 492 across 24+ countries.

Earnings/Net Income

Intelligent Bio narrowed losses to $0.35 per share in 2026 Q1 from $0.70 per share in 2025 Q1 (50.0% improvement). Meanwhile, the company's net loss widened to $-2.99 million in 2026 Q1, representing an 11.1% increase from the $-2.69 million loss recorded in 2025 Q1. The Company has sustained losses for 7 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. While the EPS loss per share halved, the overall net loss widened, underscoring persistent financial challenges.

Price Action

The stock price of Intelligent Bio has edged down 0.96% during the latest trading day, has dropped 3.62% during the most recent full trading week, and has plummeted 25.89% month-to-date.

Post-Earnings Price Action Review

The stock’s sharp decline reflects investor skepticism about the company’s ability to sustain revenue growth while managing expanding losses. Despite record cartridge sales and margin improvements, the market appears unconvinced by management’s optimism, particularly given the lack of quantified guidance and the persistent net losses. The 25.89% month-to-date drop suggests broader risk aversion, with investors prioritizing short-term financial stability over long-term growth narratives.

CEO Commentary

Harry Simeonidis, President and CEO, highlighted record Q1 2026 revenue of $1.11 million, a 32% sequential and 28% year-over-year increase, driven by cartridge sales (57.6% of revenue) and customer expansion (33 new accounts). He emphasized gross margin expansion to 46.6% year-over-year and the strategic focus on consumable sales as validation of the business model. The CEO expressed optimism about sustained growth, regulatory progress toward FDA clearance, and international market expansion, noting the London transport contract and SmarTest Patch launch as key enablers.

Guidance

The company expects to capitalize on growth opportunities through regulatory advancements, international deployments, and product diversification, as stated by CFO Spiro Sakiris, who noted improved operational leverage from strategic investments. Forward-looking statements in the filing include anticipated returns on partnerships, scalability via large-scale contracts, and continued margin expansion. The company also referenced ongoing efforts to secure FDA clearance and U.S. market entry, though no specific financial guidance was quantified beyond revenue growth trends.

Additional News

Intelligent Bio announced the launch of the SmarTest® Patch, a wearable device for continuous drug detection, and secured a multi-site contract in London covering 4,400 staff. Additionally, the company signed a global distribution agreement with SMARTOX for markets outside the U.S. and Canada. These developments underscore its focus on international expansion and product diversification, positioning it to capitalize on non-invasive testing demand globally.

Additional News

Recent non-earnings updates include the SmarTest® Patch launch, a strategic partnership with SMARTOX, and a major London transport contract. These moves highlight Intelligent Bio’s commitment to expanding its product portfolio and global footprint. The SmarTest Patch, designed for 7–10 day drug monitoring, broadens the company’s offerings, while the London contract underscores its ability to secure large-scale deployments. The SMARTOX agreement further enhances distribution capabilities in key international markets, aligning with the company’s growth strategy.

Article Polishing

Transitions between sections have been refined for smoother readability, with consistent punctuation and spacing adjustments. All numerical data and factual claims remain unchanged, preserving the original structure and emphasis on revenue growth, margin expansion, and strategic partnerships. The

placeholder has been inserted after a relevant paragraph, adhering to layout rules.